LABU holdings: 169 positions
LABU held swaps on SPSIBI worth 231.5% of its net assets on Oct 22, 2026. With the 68.5% it holds directly, its exposure is 300.0%.
The largest 100 of 169 positions
| # | Holding | Weight ↓ |
|---|---|---|
| 1 | SPSIBI swap asset leg | 51.44% |
| 2 | SPSIBI swap asset leg | 49.87% |
| 3 | SPSIBI swap asset leg | 45.41% |
| 4 | SPSIBI swap asset leg | 36.06% |
| 5 | SPSIBI swap asset leg | 30.57% |
| 6 | SPSIBI swap asset leg | 15.50% |
| 7 | SPSIBI swap asset leg | 2.69% |
| 8 | Moderna Inc | 1.53% |
| 9 | Natera Inc | 1.24% |
| 10 | Biogen Inc | 1.23% |
| 11 | Halozyme Therapeutics Inc | 1.19% |
| 12 | United Therapeutics Corp | 1.18% |
| 13 | Amgen Inc | 1.17% |
| 14 | Abbvie Inc | 1.16% |
| 15 | Exelixis Inc | 1.14% |
| 16 | Gilead Sciences Inc | 1.10% |
| 17 | Twist Bioscience Corp | 1.10% |
| 18 | Iovance Biotherapeutics Inc | 1.10% |
| 19 | Spyre Therapeutics Inc | 1.09% |
| 20 | Vertex Pharmaceuticals Inc | 1.05% |
| 21 | Regeneron Pharmaceuticals | 1.04% |
| 22 | Alkermes PLC | 0.99% |
| 23 | TG Therapeutics Inc | 0.99% |
| 24 | Protagonist Therapeutics Inc | 0.98% |
| 25 | PTC Therapeutics Inc | 0.95% |
| 26 | Incyte Corp | 0.95% |
| 27 | Neurocrine Biosciences Inc | 0.94% |
| 28 | Krystal Biotech Inc | 0.94% |
| 29 | Crispr Therapeutics AG | 0.94% |
| 30 | Revolution Medicines Inc | 0.92% |
| 31 | Bridgebio Pharma Inc | 0.92% |
| 32 | Roivant Sciences Ltd | 0.92% |
| 33 | Oruka Therapeutics Inc | 0.91% |
| 34 | Alnylam Pharmaceuticals Inc | 0.90% |
| 35 | Biomarin Pharmaceutical Inc | 0.90% |
| 36 | Vaxcyte Inc | 0.86% |
| 37 | Grail Inc | 0.86% |
| 38 | Cytokinetics Inc | 0.86% |
| 39 | Madrigal Pharmaceuticals Inc | 0.85% |
| 40 | Cogent Biosciences Inc | 0.84% |
| 41 | Kymera Therapeutics Inc | 0.82% |
| 42 | Erasca Inc | 0.81% |
| 43 | Travere Therapeutics Inc | 0.81% |
| 44 | Ionis Pharmaceuticals Inc | 0.80% |
| 45 | Tango Therapeutics Inc | 0.79% |
| 46 | Praxis Precision Medicines I | 0.77% |
| 47 | Kodiak Sciences Inc | 0.76% |
| 48 | Insmed Inc | 0.75% |
| 49 | Dianthus Therapeutics Inc | 0.75% |
| 50 | Rhythm Pharmaceuticals Inc | 0.74% |
| 51 | Veracyte Inc | 0.74% |
| 52 | Arrowhead Pharmaceuticals in | 0.72% |
| 53 | Mirum Pharmaceuticals Inc | 0.71% |
| 54 | Arcutis Biotherapeutics Inc | 0.68% |
| 55 | Immunitybio Inc | 0.67% |
| 56 | CG Oncology Inc | 0.67% |
| 57 | Caredx Inc | 0.63% |
| 58 | Relay Therapeutics Inc | 0.62% |
| 59 | Viking Therapeutics Inc | 0.61% |
| 60 | Beam Therapeutics Inc | 0.58% |
| 61 | Ultragenyx Pharmaceutical in | 0.56% |
| 62 | Celcuity Inc | 0.54% |
| 63 | Scholar Rock Holding Corp | 0.53% |
| 64 | Dyne Therapeutics Inc | 0.48% |
| 65 | Sellas Life Sciences Group I | 0.45% |
| 66 | Agios Pharmaceuticals Inc | 0.44% |
| 67 | Immunovant Inc | 0.43% |
| 68 | Recursion Pharmaceuticals-A | 0.41% |
| 69 | Ideaya Biosciences Inc | 0.40% |
| 70 | Denali Therapeutics Inc | 0.40% |
| 71 | Viridian Therapeutics Inc | 0.40% |
| 72 | Summit Therapeutics Inc | 0.39% |
| 73 | Nurix Therapeutics Inc | 0.39% |
| 74 | Biohaven Ltd | 0.38% |
| 75 | Disc Medicine Inc | 0.38% |
| 76 | Sarepta Therapeutics Inc | 0.37% |
| 77 | Biocryst Pharmaceuticals Inc | 0.37% |
| 78 | Vera Therapeutics Inc | 0.37% |
| 79 | Hyperliquid Strategies | 0.36% |
| 80 | Acadia Pharmaceuticals Inc | 0.35% |
| 81 | Adma Biologics Inc | 0.34% |
| 82 | Intellia Therapeutics Inc | 0.33% |
| 83 | Vericel Corp | 0.33% |
| 84 | Uniqure NV | 0.33% |
| 85 | Celldex Therapeutics Inc | 0.32% |
| 86 | Absci Corp | 0.32% |
| 87 | Novavax Inc | 0.32% |
| 88 | Palvella Therapeutics Inc | 0.32% |
| 89 | Arcus Biosciences Inc | 0.28% |
| 90 | First Tracks Biotherapeutics | 0.26% |
| 91 | Nektar Therapeutics | 0.26% |
| 92 | Precigen Inc | 0.25% |
| 93 | Immunome Inc | 0.25% |
| 94 | Syndax Pharmaceuticals Inc | 0.24% |
| 95 | Stoke Therapeutics Inc | 0.23% |
| 96 | Xencor Inc | 0.23% |
| 97 | Oric Pharmaceuticals Inc | 0.23% |
| 98 | Inhibrx Biosciences Inc | 0.22% |
| 99 | Mineralys Therapeutics Inc | 0.22% |
| 100 | Anaptysbio Inc | 0.21% |
| Goldman Finl Sq Trsry Inst 506 | 18.59% | |
| Dreyfus Govt Cash Man Ins | 15.83% | |
| Goldman Sachs Fin Gov 465 Institut | 0.35% | |
| Dreyfus Trsry Securities Cash Mgmt | 0.04% |
Source: Direxion’s daily holdings file. Data as of Oct 22, 2026. Updated each trading day. Report a data error
The book
What this list is
How the list is built
Each weight is the share of net assets the issuer’s own daily file gives, largest first. A swap line’s weight is the exposure it gives the fund, not money the fund paid. Cash and other net assets are in their own row and are not a position. A negative weight is a short or an offsetting contract. A swap’s Tracks column is the name its line gives what it is written on. Names are set in title case where the source used capitals. How books are read.
Weights are as the source states them, largest first.
ETFIQ links to the documents behind every figure; a link is not an endorsement. ETFIQ is an independent publisher and makes no recommendations; every figure is calculated from published data. Standards and sources →
Cite this pageCitation, APA and Markdown
ETFIQ, Holdings of LABU, data as of Oct 22, 2026. https://etfiq.com/funds/labu/holdings/
ETFIQ. (Oct 22, 2026). Holdings of LABU. Retrieved from https://etfiq.com/funds/labu/holdings/
[Holdings of LABU (ETFIQ, Oct 22, 2026)](https://etfiq.com/funds/labu/holdings/)
Free to use with attribution for figures ETFIQ computes; issuer data stays under its owner's terms. The underlying files are at Open data.